<DOC>
	<DOCNO>NCT02441309</DOCNO>
	<brief_summary>This Bayesian design multi-arm , multi-centre , open label phase II study . The target sample size 40 patient recruit 8 EU country , may revise light interim analysis . Patients relapse metastatic osteosarcoma divide three treatment group . They either surgery biopsy six week exposure either Mifamurtide alone , Ifosfamide alone , Mifamurtide combine Ifosfamide . They receive treatment maximum 42 36 week total ( depend Arm ) , patient able receive 36 week Mifamurtide treatment .</brief_summary>
	<brief_title>A Eurosarc Study Mifamurtide Advanced Osteosarcoma ( MEMOS )</brief_title>
	<detailed_description>Osteosarcoma ( OS ) common primary tumour arise bone . There currently approve treatment surgery metastatic recurrent osteosarcoma refractory chemotherapy . Patients deem unresectable normally receive chemotherapy prior attempt resection . The addition chemotherapy surgery metastatic recurrent osteosarcoma may improve response rate . MEPACT ( Mifamurtide , MTP-PE ) license use adjuvant osteosarcoma setting ; indicated child , adolescent young adult treatment high-grade resectable non-metastatic osteosarcoma macroscopically complete surgical resection . It use combination post-operative multi-agent chemotherapy . This Bayesian design multi-arm , multi-centre open-label phase II study patient metastatic and/or recurrent osteosarcoma , investigate patient osteosarcoma may respond good others mifamurtide give alone combination ifosfamide . Patients relapse metastatic osteosarcoma divide three treatment group ( Arms ) . Depending current disease status , patient may either Registered Arm A ( resectable group ) , receive Mifamurtide alone ; Randomised Arm B/C ( non-resectable group ) , receive mifamurtide combination ifosfamide . Arm A - Mifamurtide alone ; Arm B - Ifosfamide alone 6 week Ifosfamide + mifamurtide 6 week , mifamurtide alone 30 week ; Arm C - Ifosfamide + mifamurtide 12 week mifamurtide alone 24 week . All participant receive 36 week mifamurtide . Biopsies ( resect tumour sample ) obtain 6 week therapy interval order determine pharmacodynamic endpoint . The target sample size 40 patient . An interim analysis perform primary efficacy endpoint .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Mifamurtide</mesh_term>
	<mesh_term>Acetylmuramyl-Alanyl-Isoglutamine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<criteria>1 . Relapsed osteosarcoma ( first , second , third relapse , patient recover chemotherapy investigational drug/agent treatment , radiotherapy surgical procedure ) . 2 . Histological confirm diagnosis osteosarcoma original presentation . 3 . Tumour biopsy accessible resectable site . 4 . Progressive disease document image within 3 month entry trial . 5 . At least one measurable lesion CT scan ( RECIST ) perform past 21 day prior trial entry . 6 . Male female , age ≥ 16 year 65 ( ≥18 base institutional practice Teenage Young Adult Cancer patient ) . 7 . Life expectancy least 3 month . 8. WHO performance score 0 2 . 9 . The patient willing able comply protocol schedule followup visit examination . 10 . Written ( sign date ) inform consent . 11 . Cardiac shorten fraction ≥ 28 % ejection fraction ≥ 45 % 12 . Renal function adequate ifosfamide treatment ( GFR per table , renal function screen test per local practice ) 13 . Haematological biochemical index within range show : Lab Test Value require Haemoglobin ( Hb ) ≥ 9 g/dL ( Previous transfusion allow ) Absolute neutrophil count ( ANC ) &gt; =1.0 x 10*9/L without growth factor support Platelet count &gt; 80.x 10*9/L ( Previous transfusion allow ) Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) age ( except Gilbert 's syndrome patient ) Serum alanine aminotransferase ( ALT ) and/or Aspartate aminotransferase ( AST ) &lt; 2.5 × ULN age , &lt; 2.5 × ULN age Serum creatinine Normal range age Glomerular filtration rate ( GFR ) ( calculate 51CrEDTA/99mTcDTPA clearance ) &gt; 40ml/min deem resectable ( Arm A ) , &gt; 60ml/min deem resectable ( Arm B C ) 1 . Pregnant breastfeed woman . Men woman childbearing potential unless effective method contraception use study treatment least 7 day last mifamurtide dose ( see section 5.1 Informed consent Contraceptive/ Pregnancy counsel ) . 2 . Previous treatment mifamurtide mifamurtidelike drug* clinical trial set treatment metastatic and/or recurrent osteosarcoma six month prior registration . 3 . Contraindications lung biopsy . 4 . Hypersensitivity ifosfamide component formulation . 5 . Previously diagnose brain metastasis . 6 . Significant active cardiac disease include : uncontrolled high blood pressure ( great 2 standard deviation mean age systolic blood pressure ( SBP ) diastolic blood pressure ( DBP ) , unstable angina , congestive heart failure , myocardial infarction within previous 6 month , serious cardiac arrhythmia history pericarditis myocarditis 7 . Treatment investigational agent , participation another interventional clinical trial within 21 day prior enrolment . 8 . Major surgery within 21 day prior first study biopsy 9 . Currently take highdose nonsteroidal antiinflammatory drug ( NSAIDs ) corticosteroid treatment 10 . Concurrent use ciclosporin calcineurin inhibitor . 11 . Any psychological , social medical condition , physical examination find laboratory abnormality Investigator considers would make patient poor trial candidate could interfere protocol compliance interpretation trial result . 12 . Any active malignancy , exception adequately treat conebiopsied situ carcinoma cervix uteri nonmelanoma skin lesion . 13 . Patients know serologically positive Hepatitis B , Hepatitis C HIV . mifamurtidelike drug include GCSF , GMCSF , interferon macrophage activate molecule .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic and/or Recurrent Osteosarcoma</keyword>
</DOC>